Entity
CS18 (Experimental Cancer Resistance-Breaking Drug)
CS18 is an experimental compound shown in preclinical studies to disable tumor resistance mechanisms and restore chemotherapy sensitivity in resistant lung cancer cells, representing an early-stage but potentially significant advance in combination cancer therapy.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
CS18 is a new experimental drug that may help break through cancer drug resistance by disabling several of the defenses tumors use to survive treatment (ScienceDaily, September 23). In preclinical studies, CS18 reportedly strengthened existing therapies, restored drug sensitivity in resistant lung cancer cells, and slowed tumor growth in animal models (ScienceDaily, September 23).
The drug is still in early-stage development, with results so far limited to cell and animal models rather than human trials. If it progresses toward clinical testing, it could become strategically significant for pharmaceutical licensing, IP disputes, and oncology drug combination markets — an area worth tracking as data matures.